- Home
- AUTL vs NUVB Comparison
AUTL vs NUVB Comparison
Compare AUTL & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- NUVB
- Stock Information
- Founded
- AUTL 2014
- NUVB 2018
- Country
- AUTL United Kingdom
- NUVB United States
- Employees
- AUTL N/A
- NUVB N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- AUTL Health Care
- NUVB Health Care
- Exchange
- AUTL Nasdaq
- NUVB Nasdaq
- Market Cap
- AUTL 625.4M
- NUVB 679.9M
- IPO Year
- AUTL 2018
- NUVB N/A
- Fundamental
- Price
- AUTL $2.48
- NUVB $2.38
- Analyst Decision
- AUTL Strong Buy
- NUVB Strong Buy
- Analyst Count
- AUTL 5
- NUVB 6
- Target Price
- AUTL $9.32
- NUVB $7.83
- AVG Volume (30 Days)
- AUTL 1.9M
- NUVB 8.9M
- Earning Date
- AUTL 08-07-2025
- NUVB 08-04-2025
- Dividend Yield
- AUTL N/A
- NUVB N/A
- EPS Growth
- AUTL N/A
- NUVB N/A
- EPS
- AUTL N/A
- NUVB N/A
- Revenue
- AUTL $9,011,000.00
- NUVB $10,957,000.00
- Revenue This Year
- AUTL $461.76
- NUVB $101.21
- Revenue Next Year
- AUTL $112.66
- NUVB $410.28
- P/E Ratio
- AUTL N/A
- NUVB N/A
- Revenue Growth
- AUTL N/A
- NUVB N/A
- 52 Week Low
- AUTL $1.11
- NUVB $1.54
- 52 Week High
- AUTL $5.00
- NUVB $3.97
- Technical
- Relative Strength Index (RSI)
- AUTL 69.05
- NUVB 55.57
- Support Level
- AUTL $2.24
- NUVB $2.03
- Resistance Level
- AUTL $2.44
- NUVB $2.15
- Average True Range (ATR)
- AUTL 0.12
- NUVB 0.14
- MACD
- AUTL -0.01
- NUVB 0.03
- Stochastic Oscillator
- AUTL 95.96
- NUVB 85.22
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).